Patent US3556657A successfully refreshed from Google Patents.
Patent US5261885A successfully refreshed from Google Patents.
Patent US5589173A successfully refreshed from Google Patents.
US5589173A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and therapeutic compositions for the treatment of myocardial infarction
Assignee: Genentech Inc
•
Filing: 1994-06-16
•
Granted: 1996-12-31
•
Expires: 2014-06-16
Abstract
Abstract The present invention relates to a method and therapeutic composition for the treatment of myocardial infarction comprising administration of a tissue factor protein antagonist and a thrombolytic agent.
Inventors
- 👤 Donogh P. O'Brien
- 👤 Gordon A. Vehar
- 👤 Josiah N. Wilcox
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:39
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; A; A61; A61K; A61K39/00; A61K39/395; A61K45/00; A61K45/06; A61K38/00
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
67 words
A method for dissolving and preventing reformation of an occluding thrombus precipated by rupture of and atheorosclerotic plaque in a mammal in need thereof comprising, adminstering to said mammal a tissue factor protein antagonist which neutralizes the procoagulant activity of tissue factor in an amount effective to prevent the reformation of the occluding thrombus and a thrombolytic agent in an amount effective to dissolve the occluding thrombus.
Claim 2
Independent Claim
67 words
A method for dissolving and preventing reformation of an occluding thrombus precipated by rupture of and atheorosclerotic plaque in a mammal in need thereof comprising, adminstering to said mammal a tissue factor protein antagonist which neutralizes the procoagulant activity of tissue factor in an amount effective to prevent the reformation of the occluding thrombus and a thrombolytic agent in an amount effective to dissolve the occluding thrombus.
Claim 3
Dependent Claim
23 words
The method of claim 1 wherein said throbolytic agent is selected from the group consisting of streptokinase, urokinase, prourokinase and tissue-type plasminogen activator.
Claim 4
Dependent Claim
13 words
The method of claim 2 wherein said thromolytic agent is tissue-type plasminogen activator.
Claim 5
Dependent Claim
51 words
The method of claim 1 wherein the tissue factor protein antagonist is given at a dose of about in the range of 0.01-25.0 mg per kg of patient weight and the thrombolytic agent is given at a dose of about in the range of 0.01-2.5 mg per kg of patient weight.
Claim 6
Dependent Claim
12 words
The method according to claim 1 wherein the administration is by bolus.
Claim 7
Dependent Claim
12 words
The method of claim 1 wherein the adminstration by the intraveous infusion.
Claim 8
Dependent Claim
30 words
The method according to claim 5 wherein the mammal is administered a first bolus containing the tissue factor protein antagonist and subsequently administered a second bolus containing the thrombolytic agent.
Claim 9
Dependent Claim
30 words
The method according to claim 5 wherein the patient is administered a first bolus containing the thrombolytic agent and subsequently administered a second bolus containing the tissue factor protein antagonist.
Claim 10
Dependent Claim
16 words
The method according to claim 7 in which the tissue factor protein antagonist is an antibody.
Claim 11
Dependent Claim
14 words
The method according to claim 9 in which the antibody is a polyclonal antibody.
Claim 12
Dependent Claim
14 words
The method according to claim 9 in which the antibody is a monoclonal antibody.
Claim 13
Dependent Claim
13 words
The method according to claim 10 in which the mammal is a human.
Claim 14
Dependent Claim
16 words
The method according to claim 8 in which the tissue factor protein antagonist is an antibody.
Claim 15
Dependent Claim
13 words
The method according to claim 11 in which the mammal is a human.
References Cited (Backward Citations)
US4416812A
Cited
US4470968A
Cited
US4473553A
Cited
EP0266993A2
Cited
US5017556A
Cited
US5110730A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-12-31 | 2000-07-01 | 2000-12-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-12-31 | 2004-07-01 | 2004-12-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-12-31 | 2008-07-01 | 2008-12-31 | $7700.00 | Window Closed / Lapsed |